238 related articles for article (PubMed ID: 25603821)
1. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
2. Why dried blood spots are an ideal tool for CYP1A2 phenotyping.
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2014 Aug; 53(8):763-71. PubMed ID: 24980692
[TBL] [Abstract][Full Text] [Related]
3. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.
Perera V; Gross AS; McLachlan AJ
Biomed Chromatogr; 2010 Oct; 24(10):1136-44. PubMed ID: 20853468
[TBL] [Abstract][Full Text] [Related]
4. An optimized and validated SPE-LC-MS/MS method for the determination of caffeine and paraxanthine in hair.
De Kesel PM; Lambert WE; Stove CP
Talanta; 2015 Nov; 144():62-70. PubMed ID: 26452792
[TBL] [Abstract][Full Text] [Related]
5. Analysis of caffeine and paraxanthine in human saliva with ultra-high-performance liquid chromatography for CYP1A2 phenotyping.
Jordan NY; Mimpen JY; van den Bogaard WJ; Flesch FM; van de Meent MH; Torano JS
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jul; 995-996():70-3. PubMed ID: 26038236
[TBL] [Abstract][Full Text] [Related]
6. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
Fuhr U; Rost KL
Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
[TBL] [Abstract][Full Text] [Related]
7. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers.
Simon T; Becquemont L; Hamon B; Nouyrigat E; Chodjania Y; Poirier JM; Funck-Brentano C; Jaillon P
Br J Clin Pharmacol; 2001 Nov; 52(5):601-4. PubMed ID: 11736870
[TBL] [Abstract][Full Text] [Related]
8. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping.
Koch JP; ten Tusscher GW; Koppe JG; Guchelaar HJ
Biomed Chromatogr; 1999 Jun; 13(4):309-14. PubMed ID: 10416066
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
11. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Faber MS; Jetter A; Fuhr U
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
[TBL] [Abstract][Full Text] [Related]
12. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio.
Doude van Troostwijk LJ; Koopmans RP; Guchelaar HJ
Fundam Clin Pharmacol; 2003 Jun; 17(3):355-62. PubMed ID: 12803575
[TBL] [Abstract][Full Text] [Related]
13. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
Backman JT; Granfors MT; Neuvonen PJ
Eur J Clin Pharmacol; 2006 Jun; 62(6):451-61. PubMed ID: 16758262
[TBL] [Abstract][Full Text] [Related]
14. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
[TBL] [Abstract][Full Text] [Related]
15. CYP1A2 phenotyping in dried blood spots and microvolumes of whole blood and plasma.
De Kesel PM; Lambert WE; Stove CP
Bioanalysis; 2014; 6(22):3011-24. PubMed ID: 25096793
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a reversed-phase HPLC method for CYP1A2 phenotyping by use of a caffeine metabolite ratio in saliva.
Begas E; Kouvaras E; Tsakalof AK; Bounitsi M; Asprodini EK
Biomed Chromatogr; 2015 Nov; 29(11):1657-63. PubMed ID: 25891161
[TBL] [Abstract][Full Text] [Related]
17. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
Rasmussen BB; Brøsen K
Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
[TBL] [Abstract][Full Text] [Related]
18. The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained?
Spigset O; Hägg S; Söderström E; Dahlqvist R
Pharmacogenetics; 1999 Jun; 9(3):409-12. PubMed ID: 10471076
[No Abstract] [Full Text] [Related]
19. Paraxanthine/caffeine ratio: as an index for CYP1A2 activity in polycyclic aromatic hydrocarbons exposed subjects.
Wittayalertpanya S; Hinsui Y; Lawanprasert S
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S310-7. PubMed ID: 12930004
[TBL] [Abstract][Full Text] [Related]
20. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.
Terziivanov D; Bozhinova K; Dimitrova V; Atanasova I
Clin Pharmacokinet; 2003; 42(15):1393-409. PubMed ID: 14674790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
